Multicenter phase II placebo-controlled, masked, randomized superiority clinical trial of omalizumab vs placebo in individuals with COPD having sensitization and exposure to indoor allergens
This study is a multinational, multi-center, observational, prospective, cohort study of patients with refractory chronic cough/unexplained chronic cough (RCC/UCC) and patients without RCC/UCC using primary data collection.
